A. Banat

Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · Blood · 2009 · 157 citations

Medicine, Oncology, Pharmacotherapy +6

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias Rummel, Ulrich von Gruenhagen, N. Niederle et al. · Blood · 2007 · 65 citations

Medicine, Oncology, Pharmacotherapy +12

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · Journal of Clinical Oncology · 2012 · 50 citations

Medicine, Oncology, Pharmacotherapy +9

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · Journal of Clinical Oncology · 2012 · 39 citations

Medicine, Oncology, Pharmacotherapy +9

Bendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas: Long-term follow-up of a phase II study

Mathias Rummel, J. Atta, Manfred Welslau et al. · Journal of Clinical Oncology · 2007 · 16 citations

Medicine, Oncology, Pharmacotherapy +14